Notice about cookies

Close

This website uses a limited number of cookies to improve your browsing experience. For further information (including how to withdraw consent), please refer to our Cookie Policy. By clicking Accept below or continuing to use this website (including closing this message), you confirm that you have read and consent to our use of cookies as detailed in our Cookie Policy.

Accept

UCB's Global Corporate Website
Welcome to UCB in the United States

Categories

Archives

Dec

23

UCB Announces FDA Acceptance of BLA Resubmission for Bimekizumab

Read More Share:linkedin| twitter| email

Dec

14

UCB’s Health Equity First Approach to Addressing Population Health Challenges

Read More Share:linkedin| twitter| email

Dec

13

Employee Spotlight: Leah VanderVeen and Her Time as a Court Appointed Special Advocate for Foster Children

Read More Share:linkedin| twitter| email

Dec

09

UCB Announces Positive Phase 3 Studies for Bimekizumab in Hidradenitis Suppurativa

Read More Share:linkedin| twitter| email

Dec

07

The Lancet Publishes Results from Two Bimekizumab Phase 3 Studies in Psoriatic Arthritis

Read More Share:linkedin| twitter| email

Dec

01

UCB to present data at the American Epilepsy Society 76th Annual Meeting 2022 supporting a decades-long commitment to transforming epilepsy care

Read More Share:linkedin| twitter| email

© 2009 - 2020 UCB, Inc., Atlanta. All rights reserved.
USPR-CORP-0115-00003(2)